Literature DB >> 24912861

Characteristics, risk factors and outcomes of adult cancer patients with extensively drug-resistant Pseudomonas aeruginosa infections.

G Samonis1, K Z Vardakas, D P Kofteridis, D Dimopoulou, A M Andrianaki, I Chatzinikolaou, E Katsanevaki, S Maraki, M E Falagas.   

Abstract

OBJECTIVE: To evaluate the characteristics and outcomes of cancer patients with extensively drug-resistant (XDR) Pseudomonas aeruginosa infections.
METHODS: This was a retrospective cohort of P. aeruginosa infections in cancer patients in Crete, Greece. Patients were followed until discharge. Mortality, predictors of mortality and risk factors for XDR P. aeruginosa infection were studied.
RESULTS: Ninety seven episodes (89 patients) of P. aeruginosa infections (52 with bacteremia) were included in the study. In 22 cases, the infection was due to XDR isolates. All XDR isolates were susceptible to colistin and variably resistant to almost all other antibiotics. The multivariate analysis showed that the independent risk factors for XDR P. aeruginosa infection were hematologic malignancy (OR 40.7, 95 % CI 4.5-367.6) and prior fluoroquinolone use (OR 11.0, 95 % CI 2.0-60.5); lymphopenia was inversely associated with XDR infections (OR 0.16, 95 % CI 0.03-0.92). Mortality was 43 %; infection-related mortality was 24 %. Bacteremia (OR 8.47, 95 % CI 2.38-30.15), infection due to XDR isolates (OR 5.11, 95 % CI 1.15-22.62) and age (OR 1.05, 95 % CI 1.00-1.09) were independently associated with mortality.
CONCLUSION: Mortality in cancer patients with P. aeruginosa infections was high. Infection due to XDR isolates was independently associated with mortality.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24912861     DOI: 10.1007/s15010-014-0635-z

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  39 in total

1.  Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients.

Authors:  M Hilf; V L Yu; J Sharp; J J Zuravleff; J A Korvick; R R Muder
Journal:  Am J Med       Date:  1989-11       Impact factor: 4.965

2.  Pseudomonas aeruginosa bacteraemia in cancer patients.

Authors:  Vladimir Krcmery; Jana Koprnova; Maria Gogova; Eva Grey; Jarmila Korcova
Journal:  J Infect       Date:  2006-04-18       Impact factor: 6.072

3.  Clinical characteristics and risk factors for mortality in patients with bacteremia caused by Pseudomonas aeruginosa.

Authors:  Tetsuya Horino; Akio Chiba; Shinji Kawano; Tetsuro Kato; Fumiya Sato; Yukio Maruyama; Yasushi Nakazawa; Koji Yoshikawa; Masaki Yoshida; Seiji Hori
Journal:  Intern Med       Date:  2012-01-01       Impact factor: 1.271

Review 4.  Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature.

Authors:  M E Falagas; P Kopterides
Journal:  J Hosp Infect       Date:  2006-07-05       Impact factor: 3.926

Review 5.  Impact of antibiotic MIC on infection outcome in patients with susceptible Gram-negative bacteria: a systematic review and meta-analysis.

Authors:  Matthew E Falagas; Giannoula S Tansarli; Petros I Rafailidis; Anastasios Kapaskelis; Konstantinos Z Vardakas
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

6.  Risk factors for infections with multidrug-resistant Pseudomonas aeruginosa in patients with cancer.

Authors:  Norio Ohmagari; Hend Hanna; Linda Graviss; Brenda Hackett; Cheryl Perego; Virginia Gonzalez; Tanya Dvorak; Holly Hogan; Ray Hachem; Kenneth Rolston; Issam Raad
Journal:  Cancer       Date:  2005-07-01       Impact factor: 6.860

7.  Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution.

Authors:  E González-Barca; A Fernández-Sevilla; J Carratalá; A Grañena; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-04       Impact factor: 3.267

8.  A prospective study of characteristics and outcomes of bacteremia in patients with solid organ or hematologic malignancies.

Authors:  George Samonis; Konstantinos Z Vardakas; Sofia Maraki; Giannoula S Tansarli; Dimitra Dimopoulou; Diamantis P Kofteridis; Angeliki M Andrianaki; Matthew E Falagas
Journal:  Support Care Cancer       Date:  2013-04-27       Impact factor: 3.603

9.  Risk factors of oropharyngeal carriage of Pseudomonas aeruginosa among patients from a Medical-Surgical Intensive Care Unit.

Authors:  Carlos Magno Castelo Branco Fortaleza; Lígia Castellon Figueiredo; Carolina Contador Beraldo; Edson Carvalho de Melo; Patrícia Maria Sales Póla; Valéria Drummond Nagem Aragão
Journal:  Braz J Infect Dis       Date:  2009-06       Impact factor: 1.949

10.  Nationwide study of invasive Pseudomonas aeruginosa infection in Norway: importance of underlying disease.

Authors:  Bjørn G Iversen; Arne B Brantsaeter; Preben Aavitsland
Journal:  J Infect       Date:  2008-07-09       Impact factor: 6.072

View more
  14 in total

1.  Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to Pseudomonas aeruginosa.

Authors:  C Gudiol; A Albasanz-Puig; J Laporte-Amargós; N Pallarès; A Mussetti; I Ruiz-Camps; P Puerta-Alcalde; E Abdala; C Oltolini; M Akova; M Montejo; M Mikulska; P Martín-Dávila; F Herrera; O Gasch; L Drgona; H Paz Morales; A-S Brunel; E García; B Isler; W V Kern; I Morales; G Maestro-de la Calle; M Montero; S S Kanj; O R Sipahi; S Calik; I Márquez-Gómez; J I Marin; M Z R Gomes; P Hemmatti; R Araos; M Peghin; J L Del Pozo; L Yáñez; R Tilley; A Manzur; A Novo; J Carratalà
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

2.  International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).

Authors:  Brian T Tsuji; Jason M Pogue; Alexandre P Zavascki; Mical Paul; George L Daikos; Alan Forrest; Daniele R Giacobbe; Claudio Viscoli; Helen Giamarellou; Ilias Karaiskos; Donald Kaye; Johan W Mouton; Vincent H Tam; Visanu Thamlikitkul; Richard G Wunderink; Jian Li; Roger L Nation; Keith S Kaye
Journal:  Pharmacotherapy       Date:  2019-01       Impact factor: 6.251

3.  Molecular epidemiological survey of bacteremia by multidrug resistant Pseudomonas aeruginosa: the relevance of intrinsic resistance mechanisms.

Authors:  Raquel Cristina Cavalcanti Dantas; Rebecca Tavares E Silva; Melina Lorraine Ferreira; Iara Rossi Gonçalves; Bruna Fuga Araújo; Paola Amaral de Campos; Sabrina Royer; Deivid William da Fonseca Batistão; Paulo Pinto Gontijo-Filho; Rosineide Marques Ribas
Journal:  PLoS One       Date:  2017-05-08       Impact factor: 3.240

4.  Estimating the burden of antimicrobial resistance: a systematic literature review.

Authors:  Nichola R Naylor; Rifat Atun; Nina Zhu; Kavian Kulasabanathan; Sachin Silva; Anuja Chatterjee; Gwenan M Knight; Julie V Robotham
Journal:  Antimicrob Resist Infect Control       Date:  2018-04-25       Impact factor: 4.887

5.  Impact of antibiotic resistance on outcomes of neutropenic cancer patients with Pseudomonas aeruginosa bacteraemia (IRONIC study): study protocol of a retrospective multicentre international study.

Authors:  Adaia Albasanz-Puig; Carlota Gudiol; Rocío Parody; Cristian Tebe; Murat Akova; Rafael Araos; Anna Bote; Anne-Sophie Brunel; Sebnem Calik; Lubos Drgona; Estefanía García; Philipp Hemmati; Fabián Herrera; Karim Yaqub Ibrahim; Burcu Isler; Souha Kanj; Winfried Kern; Guillermo Maestro de la Calle; Adriana Manzur; Jorge Iván Marin; Ignacio Márquez-Gómez; Pilar Martín-Dávila; Malgorzata Mikulska; José Miguel Montejo; Milagros Montero; Hugo Manuel Paz Morales; Isabel Morales; Andrés Novo; Chiara Oltolini; Maddalena Peghin; Jose Luis Del Pozo; Pedro Puerta-Alcalde; Isabel Ruiz-Camps; Oguz Resat Sipahi; Robert Tilley; Lucrecia Yáñez; Marisa Zenaide Ribeiro Gomes; Jordi Carratalà
Journal:  BMJ Open       Date:  2019-05-24       Impact factor: 2.692

Review 6.  Epidemiology and Mechanisms of Resistance of Extensively Drug Resistant Gram-Negative Bacteria.

Authors:  Emily M Eichenberger; Joshua T Thaden
Journal:  Antibiotics (Basel)       Date:  2019-04-06

7.  Clinical and treatment-related risk factors for nosocomial colonisation with extensively drug-resistant Pseudomonas aeruginosa in a haematological patient population: a matched case control study.

Authors:  Matthias Willmann; Anna M Klimek; Wichard Vogel; Jan Liese; Matthias Marschal; Ingo B Autenrieth; Silke Peter; Michael Buhl
Journal:  BMC Infect Dis       Date:  2014-12-10       Impact factor: 3.090

8.  Comparison of mono- and combination antibiotic therapy for the treatment of Pseudomonas aeruginosa bacteraemia: A cumulative meta-analysis of cohort studies.

Authors:  Su Yu Tang; Shun Wen Zhang; Jiang Dong Wu; Fang Wu; Jie Zhang; Jiang Tao Dong; Peng Guo; Da Long Zhang; Jun Ting Yang; Wan Jiang Zhang
Journal:  Exp Ther Med       Date:  2018-01-09       Impact factor: 2.447

9.  Epidemiology and risk factors of extensively drug-resistant Pseudomonas aeruginosa infections.

Authors:  Nattawan Palavutitotai; Anupop Jitmuang; Sasima Tongsai; Pattarachai Kiratisin; Nasikarn Angkasekwinai
Journal:  PLoS One       Date:  2018-02-22       Impact factor: 3.240

10.  Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis.

Authors:  Gowri Raman; Esther E Avendano; Jeffrey Chan; Sanjay Merchant; Laura Puzniak
Journal:  Antimicrob Resist Infect Control       Date:  2018-07-04       Impact factor: 4.887

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.